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Adverse outcomes after colposcopy
Sarah M Flanagan, Sue Wilson*, David Luesley, Sarah L Damery, Sheila M Greenfield
Abstract
Background: Colposcopy is an essential part of the National Health Service Cervical Screening Programme
(NHSCSP). It is used for both diagnosis and treatment of pre-cancerous cells of the cervix.
Despite colposcopy being a commonly performed and relatively invasive procedure, very little research has
explored the potential long-term impacts of colposcopic examination upon patient quality of life.
The aim of this study is to investigate and quantify any potential reduction in women’s quality of life following a
colposcopy procedure. More specifically, the degree of female sexual dysfunction and the excess risk of adverse
events in those undergoing colposcopy will be explored. If such risks are identified, these can be communicated to
women before undergoing colposcopy. It will also assist in identifying whether there are particular sub-groups at
greater risk and if so, this may lead to a re-evaluation of current recommendations concerning colposcopically
directed treatments.
Methods/design: Cohort study using postal surveys to assess sexual function and quality of life in women who
have attended for colposcopy (cases), compared with those who have not attended colposcopy (controls). The
prevalence and excess risk of female sexual dysfunction will be determined. Logistic regression will identify the
predictors of adverse outcomes.
Discussion: There are more than 400,000 colposcopy appointments each year in England, of which 134,000 are
new referrals. There is some evidence that there may be long-term implications for women treated under
colposcopy with respect to adverse obstetric outcomes, persisting anxiety, increased rates of sexual dysfunction
and reduced quality of life. Reliably establishing whether such adverse outcomes exist and the excess risk of
adverse events will facilitate informed decision-making and patient choice.
Background
Colpsocopy is an essential part of the National Health
Service Cervical Screening Programme (NHSCSP). It is
a detailed examination of the cervix, performed by a
doctor or qualified colposcopist in an outpatient setting.
Colposcopy clinics enable the diagnosis and treatment
of Cervical Intraepithelial Neoplasia (CIN) [1]. Women
are invited for colposcopy following a referral generated
via the NHSCSP recommending further investigation of
potential cell abnormalities discovered during routine
cervical screening or if they are experiencing symptoms
that warrant further investigation.
There are more than 400,000 colposcopy appoint-
ments each year, of which 134,000 are new referrals [2].
Colposcopy is therefore a relatively common procedure,
and has a treatment success rate exceeding [3] 90%.
There are typically few complications [4,5]. Very little
research has explored the long-term consequences of
colposcopic investigation, other than with respect to
recurrence of CIN [6], the incidence of cervical stenosis,
[7] and the impact on subsequent pregnancies or recur-
rence [8-11].
The long-term physical and psychological conse-
quences of invasive cancer are well described [12]. Psy-
chological well-being scores amongst cancer patients
remain lower than those of patients with other chronic
illnesses or healthy subjects irrespective of age, cancer
site, or stage of disease; and the provision of psychologi-
cal interventions for patients facing cancer treatment
has been recommended as an integral component of
cancer management [2]. Furthermore, studies exploring
the quality of life of cancer survivors suggest that fear of
the diagnostic process can be as traumatic as the effects
of cancer treatment. Longitudinal studies assessing the
consequences of hysterectomy in the treatment of early
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stage cervical carcinoma report that the majority of
women (>90%) report one or more symptoms associated
with reduced quality of life and a persistent negative
impact on sexual interest has been reported [13,14].
Jensen et al utilised a validated self-assessment question-
naire (the Sexual function-Vaginal changes Question-
naire - SVQ) and found that radical hysterectomy was
associated with a long-term reduction in patients’ sexual
interest [14].
There is a considerable body of evidence relating to
the anxiety and distress associated with an abnormal
smear, attending a colposcopy appointment, and the
diagnosis of CIN or cancer [2,13,15]. Almost all of the
published literature reports an adverse impact on anxi-
ety and quality of life associated with these clinical
investigations and diagnoses. Diagnosis of CIN has been
associated with a perceived threat to life and/or fertility,
feelings of anger and resentment [16-18], and negative
impacts upon body image and sexual functioning [19].
Diagnosis can also have a stigmatising effect [20], which
may lead women to avoid subsequent screening [21-23].
Studies have found that the main reason for non-
attendance for cervical screening is patients’ belief that
it is a test for cancer alone, and fear of a positive result
[21-23].
Treatment of CIN has an adverse effect on subsequent
fertility and obstetric outcomes [7-9]. There is some evi-
dence that women who have undergone colposcopy
report adverse effects upon their sex life [1,16-18,24-26].
Women have been reported to experience impaired sex-
ual functioning after colposcopy [19,27]. Posner and
Vessey study found that 14% of women reported that
their sex life was not ‘back to normal’ six to nine
months after colposcopy and that 19% of women’s sex
lives were adversely affected subsequent to treatment
[13].
Despite qualitative research suggesting the possibility
of long-term adverse consequences of colposcopy [13],
research has been undertaken to determine the generali-
sability of these findings or to quantify the prevalence of
these adverse impacts. Quantitative studies have to date
been small-scale, underpowered, and tend to be
restricted to the time of the abnormal smear or colpo-
scopy [19,27]. Furthermore, none have been of sufficient
size to differentiate between women who underwent col-
poscopy purely for diagnosis and those who had treat-
ment. The need to establish the long-term psychological
consequences of colposcopy has been acknowledged
[18], and a study of sufficient size and follow-up is
required.
Unanswered questions relate to: i) whether there is
a reduction in quality of life and an excess of female
sexual dysfunction (FSD) subsequent to colposcopy;
ii) the extent of any excess risk, and iii) whether the
potential adverse impacts following colposcopy dif-
fer according to the level of intervention (diagnosis
or treatment) which women undergo. This cohort
study aims to determine the association between
colposcopy and treatment for CIN and subsequent
risk of sexual dysfunction and/or reduced quality
of life.
Aims and Objectives
Primary Aim
The primary aim of this cohort study is to determine
the long-term impact of colposcopic intervention and
treatment for CIN on quality of life (QoL) and sexual
functioning.
Objectives
(1) To conduct a systematic review of the literature in
relation to colposcopy and its effect upon quality of life
(physical and psychological) including sexual
functioning.
(2) To accurately establish the prevalence of sexual
dysfunction subsequent to colposcopy.
(3) To identify any sub-groups of women who may be
at increased risk of sexual dysfunction and reduced
quality of life.
(4) To determine the need for interventions to reduce
the long-term adverse impacts of colposcopy.
Methods/design
Summary of study design
Cohort study
A short postal questionnaire will estimate the prevalence
of Female Sexual Dysfunction (FSD). A second, more
detailed questionnaire will address other aspects of QoL.
Postal questionnaires will be sent to women (n = 1050)
who have attended for colposcopy (cases), and to age
and deprivation matched controls (n = 1050) who have
not attended colposcopy. The Index of Multiple Depri-
vation (IMD 2007) used as a proxy measure for depriva-
tion [28].
Eligibility criteria
Cases: New referrals - women aged 25 to 65 who have
undergone colposcopy at least 12 months previously
(between April 2008 and March 2009). Cases will be
stratified by level of intervention.
1. Low risk - colposcopy only: no treatment or inves-
tigation (n = 350)
2. Medium risk - colposcopy with investigation/diag-
nosis i.e. punch biopsy (n = 350)
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3. High risk - colposcopy and treatment i.e. loop
excision, or cone biopsy (n = 350)
Controls: Women aged 25 to 65 who have never
undergone colposcopy (n = 1050). Controls will be age
(+/- 3 years) and deprivation score matched with
controls.
Exclusion criteria
Cases: Women who have undergone treatment which has
not been colposcopically directed, for example women
who have been treated by hysterectomy. Women with a
previous/current diagnosis of invasive cancer.
Controls: Women who have undergone colposcopy
or have been diagnosed with a gynaecological
malignancy.
Recruitment of participants
Study Population - Cases will be identified using the
patient databases of five participating NHS Colpo-
scopy units within the West Midlands. Up to four
general practices will be recruited to identify control
participants. Practices will be purposively recruited to
ensure that controls can be matched by age and IMD
2007.
Invitation method
Potential participants will receive a covering letter and a
patient information leaflet (PIL) explaining the study in
depth, with a questionnaire and freepost envelope for
questionnaire return. Questionnaires will be marked
with a unique identifier and one reminder will be sent
to all non-responders.
Responders to the first questionnaire who indicate
their willingness to participate in the next research
phase will receive a subsequent more detailed question-
naire. To maximise uptake amongst control participants,
we will provided information about how their participa-
tion will enable exploration of this under-researched
area of women’s health. A pilot/feasibility study has con-
firmed the acceptability of the data collection tools and
patient information leaflet. Feedback from this has
informed revisions of the PIL and questionnaire with a
view to maximising participation.
Data Collection tool
Questionnaire details
Initially, potential participants will receive a brief ques-
tionnaire to establish the prevalence of sexual problems
using six questions used in the National Survey of Sex-
ual Attitudes and Lifestyles (2000) [29] that relate to
sexual functioning. It also includes four basic questions
relating to general health and responders are asked to
rate their satisfaction levels with sex life and relation-
ships on a likert scales. It will also contain an open
question with space provided for participants to provide
any further comments. Participants will also be invited
to consent to receive the second questionnaire.
The second questionnaire will collect more detailed
demographic information and details of outcomes and
the predictors of adverse outcomes (Table 1).
The following validated measures will be used to mea-
sure sexual function, levels of anxiety and depression
and quality of life:
Female Sexual Function Index (FSFI) which provides
information about a woman’s sexual functioning [31].
A score below 26.5 indicates sexual dysfunction.
The Hospital Anxiety and Depression (HADS) scale,
which assesses levels of anxiety and depression.
HADS has been found to perform well in assessing
the symptom severity and caseness of anxiety disor-
ders and depression in somatic, psychiatric and
primary care patients as well as in the general popu-
lation [32]. HADS contains 14 items, each of which is
marked on a four-point sub-scale. Scores of 11 or
more on either subscale are considered to indicate a
significant ‘case ’ of psychological morbidity, while
scores of 8 to 10 represent a ‘borderline’ case, and 0
to 7 are ‘normal’ [34].
Quality of life will be measured using the WHOQOL-
BREF (The World Health Quality of Life - BREF) incor-
porating physical health, psychological health, social
relationships and environmental factors [30].
All control participants will receive the same question-
naires as the cases.
Analysis
The prevalence of FSD will be standardised to the
England and Wales population [35]. Multivariate ana-
lyses will describe patterns of differences between
Table 1 Information collected in the second questionnaire
Outcomes Quality of Life [30], sexual functioning [31], anxiety and depression [32], cervical stenosis, obstetric outcomes
Confounders Socio-demographic factors: Age, ethnicity [33], deprivation [28], relationships, education
Lifestyle factors: smoking, alcohol, problem drug use
Health-related factors: obstetric history, history of sexually transmitted disease, number of visits to GP, physical health problems
Flanagan et al. BMC Women?’?s Health 2011, 11:2
http://www.biomedcentral.com/1472-6874/11/2
Page 3 of 7
patients according to the level of investigation/treatment
associated with their colposcopy (in terms of low,
medium or high risk). FSD, anxiety and QoL will be
compared for the three different groups (low, medium
and high risk) and controls. Logistic regression analyses
including socio-demographic variables (age, ethnicity,
deprivation) and health-related factors (e.g. co-morbid-
ities) will aim to identify the predictors of adverse
outcomes (e.g. FSD).
Open comments will be analysed with the help of a
computer-package (SPSS Text Analysis for Surveys™),
by content analysis using both quantitative (e.g. number
of times a word/phrase mentioned) and qualitative tech-
niques (e.g. examples of participants’ own words to
reflect emerging themes) [36].
Justification of sample size
Each year, the five collaborating centres have 12,400
colposcopy appointments. 6693 individuals are esti-
mated to be eligible for inclusion within this study (i.e.
excluding follow-up, non-attendance, cancellation).
Eligible women comprise those treated (11.5%), not
requiring treatment (65%) and those having investiga-
tion (e.g. biopsy) but no further treatment (23.5%).
Data have been based upon colposcopy records of
three participating colposcopy units. The mean age at
colposcopy is 38 years (range 17 to 82) and the back-
ground (no colposcopy) prevalence of FSD is assumed
to be 15% [35]. To estimate a doubling in the risk of
FSD (from 15 to 30%), 160 participants are required in
each group (90% power, 5% significance). The smallest
group (high risk) comprises 770 women per annum.
Conservatively assuming a questionnaire response rate
of 50% (we usually achieve >60% [37,38], the required
sample size would be achieved through mailing 350 in
each group. Assuming an average practice list size of
6,000, that 15% [39] are aged between 20 and 40 (most
common age range for colposcopy), and that 70% have
not experienced colposcopy, 630 patients per practice
will be eligible as controls [Figure 1]. Four practices
with variability in socio-demographic profiles will be
recruited.
Practices will be identified via the Midlands Research
Practices Consortium (MidReC). This consists of a net-
work of over 600 practices, covering a representative
population of over four million residents of the West
Midlands [40].
Ethical approvals
Ethics approval has been provided by The Black Coun-
try Research Ethics Committee on 15/03/10 (reference:
10/H1202/9).
R&D approval has been recieved from four R&D
trusts: Heart of England NHS Trust, Birmingham
Women’s NHS Foundation Trust, Sandwell and West
Birmingham NHS Trust and Worcestershire PCT.
Discussion
Colposcopy is a relatively common procedure, with
over 400,000 appointments attended each year. It is an
essential part of the National Health Service Cervical
Screening Programme and enables the diagnosis and
treatment of pre-cancerous changes in the cervix.
Although it is a relatively safe procedure and an effec-
tive treatment for CIN, previous studies have indicated
that it can have adverse effects upon obstetric out-
comes and may increase the incidence of cervical ste-
nosis. Furthermore, evidence suggests that cervical
screening, undergoing colposcopy and subsequent
treatment for CIN may have adverse impacts upon
women ’s psychological, physical health and sexual
health and well-being. As these studies have been rela-
tively small or based on qualitative data, a study of suf-
ficient size is required to determine the long-term
impacts of colposcopy. In addition, none of the current
studies have been powered to differentiate between the
impacts experienced by women that underwent colpo-
scopy purely for diagnosis and those who have treat-
ment. In this study, we will stratify cases depending
upon whether patients were ‘treated’ at colposcopy,
underwent investigation (biopsy) or had no treatment
or investigation. This study will enable us to establish,
for example, if patients who were ‘treated’ experienced
adverse events to a greater extent than patients who
underwent investigation alone.
It will also assist in identifying whether there are parti-
cular population sub-groups who are more likely to be at
an increased risk of adverse effects after colposcopy. If
such risks are identified, this may lead to a reconsideration
of the benefits of earlier intervention and a re-evaluation
of the current recommendations concerning colposcopi-
cally directed treatments [4]. Women who are currently at
low risk of CIN may not be treated by colposcopy as
promptly as current guidelines indicate. This may allow
any potential abnormalities that may revert to normal to
do so without the need for more invasive investigation. It
may also be that this group of women can be monitored
via cervical screening. Women at high risk of experiencing
adverse outcomes could be monitored more closely and
offered appropriate support and advice around potential
adverse outcomes. If no excess risk is identified, we can
reassure women and clinicians that there are no adverse
outcomes associated with colposcopy in terms of psycho-
sexual and general health and well-being.
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